David Tucker
About David Tucker
David Tucker, age 60, is Executive Vice President and Chief Strategy Officer at Addus HomeCare (ADUS) since April 2022, having joined the company in July 2016 and progressed through business development and managed care leadership roles; he holds a Bachelor of Science degree from Glenville State College . For context on company performance in his current tenure, Addus delivered 2024 total shareholder return of 128.89 and reported adjusted EBITDA of $140.29 million and net income of $73.60 million .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Addus HomeCare | EVP, Chief Strategy Officer | Apr 2022–present | — |
| Addus HomeCare | EVP, Chief Development Officer | Nov 2019–2022 | — |
| Addus HomeCare | SVP, Business Development | Mar 2018–Oct 2019 | — |
| Addus HomeCare | VP, Managed Care | Jul 2016–Feb 2018 | — |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| CCS Medical, Inc. | Senior VP, Business Development | 2012–Jul 2016 | — |
Fixed Compensation
Not disclosed for David Tucker in the 2025 proxy; he is not a named executive officer in the Summary Compensation Table .
Performance Compensation
Company executive plan design (David Tucker’s specific targets not disclosed):
| Metric | Weighting | Threshold (90% of target) | Target | Maximum (110% of target) | 2024 Actual | Payout Mechanics |
|---|---|---|---|---|---|---|
| Adjusted EBITDA | 100% of annual cash and equity incentives | 50% payout at 90% of Adjusted EBITDA target | 100% payout at target | 150% payout at 110% of Adjusted EBITDA target | $143,293k, 112% of target (target revised for 2024 acquisitions/divestiture) | Linear interpolation within thresholds; actual 2024 results triggered max 150% factor for NEOs |
Notes:
- Annual executive equity grants (for NEOs) were converted into restricted stock using the closing price on Feb 21, 2025 and vest evenly over three years (Feb 21, 2026–2028) .
- The company retains Adjusted EBITDA as the sole criterion for 2025 cash and equity plans with the same 90%/110% thresholds .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Total beneficial ownership | 23,638 shares (includes SOUs as applicable) |
| Ownership % of shares outstanding | Less than 1% (18,399,139 shares outstanding as of Apr 23, 2025; table shows “* Less than one percent”) |
| Options (exercisable within 60 days of record date) | 12,500 shares |
| Unvested restricted stock | 8,735 shares; various vesting dates; will vest in full on Feb 21, 2028 |
| Pledging/margin policy | Company prohibits pledging and holding shares in margin accounts for directors, officers, employees |
| Hedging policy | Prohibits hedging and derivatives on company stock for directors, officers, employees |
| Ownership guidelines | Not disclosed in the proxy for executives |
Employment Terms
- Role and reporting: Executive Vice President and Chief Strategy Officer since April 2022 .
- Insider Trading Policy: Anti-hedging, anti-pledging, no margin accounts; standing/limit orders require consent .
- Clawback: Compensation recoupment policy adopted Nov 24, 2023 under SEC/Nasdaq rules .
- Individual employment agreement, severance, and change-of-control economics for David Tucker are not disclosed in the 2025 proxy or recent 8-Ks .
Compensation Peer Group (Benchmarking)
| Peer Companies (as used by FW Cook) |
|---|
| Amedisys, Inc. |
| Aveanna Healthcare Holdings, Inc. |
| Chemed Corporation |
| Enhabit, Inc. |
| ModivCare Inc. |
| National HealthCare Corporation |
| Option Care Health, Inc. |
| Pediatrix Medical Group, Inc. |
| RadNet, Inc. |
| Select Medical Holdings Corporation |
| The Ensign Group, Inc. |
| The Pennant Group, Inc. |
| U.S. Physical Therapy, Inc. |
Investment Implications
- Alignment: Anti-hedging/pledging policies limit misalignment risks; beneficial ownership of 23,638 shares plus 8,735 unvested RSAs (vesting fully on Feb 21, 2028) supports long-term alignment and creates retention incentives tied to three-year equity vesting cadence .
- Selling pressure: 12,500 options are currently exercisable; the 2028 full vest for RSAs is a potential supply event—monitor 10b5-1 plan filings and Form 4s into mid-February each year, especially around vesting dates .
- Pay-for-performance context: Company-wide incentives are 100% tied to Adjusted EBITDA with tight 90%/110% thresholds; 2024 actuals at 112% drove maximum payouts for NEOs, signaling a high-performance bias; while Tucker’s specific targets aren’t disclosed, senior executive incentives follow this framework .
- Retention risk: Long-dated RSAs vesting through 2028 reduce near-term flight risk; no individual severance/change-of-control terms are disclosed, so assess retention qualitatively via equity vesting and role scope .